Pharmaceutical synthesis requires large-scale ultra-pure synthesis of simple and complex molecules. Currently, the industry faces the following issues:
Pharmaceutical development is in need of process materials that provide clean chemistry with stoichiometric molecular combination with simple and safe process steps as well as the potential to be brought from single batch processes into continuous flow product generation.
SiGNa’s process development services offer an innovative service platform which bundles its stabilized reactive metal products, its know-how, and unparalleled services for the pharmaceutical industry. Our customers benefit from the effective integration of our company-wide knowledge-base.
Building from our growing product portfolio and outstanding services in the areas of synthesis and formulation, SiGNa is a highly desired R&D partner in the pharmaceutical industry.
Currently SiGNa is working on the next element in the alkali metal family, Lithium. A number of new discoveries have been made. Read More